| Hans-Günter Meyer-Thompson | Buprenorphin
Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes
Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes
An extended release version of buprenorphine was recently approved by the FDA to treat opioid use disorder. Prior research has revealed the short-term benefits of buprenorphine on traditional treatment outcomes like substance use and acute harm (e.g., overdose). Building upon this literature, the current study assessed the longer-term effects of monthly buprenorphine injections on patient-centered outcomes like quality of life and health status, suggesting improved well-being up to 1 year of treatment. (Recovery Research Institute, USA, April 2020)
https://www.recoveryanswers.org/research-post/injectable-buprenorphine-1-year-outcomes/